Mark W Vogel1, Joshua P Slusser, David O Hodge, Horng H Chen. 1. Department of Medicine, Division of Cardiovascular Diseases, and the Division of Biostatistics, Mayo Clinic College of Medicine, Mayo Clinic and Foundation, Rochester, MN 55905, USA.
Abstract
BACKGROUND: Preclinical diastolic dysfunction (PDD) has been broadly defined as subjects with left ventricular diastolic dysfunction, without the diagnosis of congestive heart failure (HF) and with normal systolic function. Our objective was to determine the risk factors associated with the progression from PDD (stage B) HF to symptomatic (stage C) HF. METHODS AND RESULTS: Using the resources of the Rochester Epidemiology Project, all residents of Olmsted County, MN, who underwent echocardiography between January 1, 2004, and December 31, 2005, and had grade 2-4 diastolic dysfunction and ejection fraction ≥50% were identified. Patients with a diagnosis of HF before or within 30 days of the echocardiogram were excluded. Patients were also excluded if they had a diagnosis of atrial fibrillation or severe mitral or aortic valve regurgitation at the time of the echocardiogram. A total of 388 patients met the inclusion criteria. The mean age of the cohort was 67±12 years, with a female (57%) predominance. Prevalence of renal insufficiency (estimated glomerular filtration rate <60 mL/min per 1.73 m(2)) was 34%. The 3-year cumulative probabilities of development of (stage C) HF, development of atrial fibrillation, cardiac hospitalization, and mortality were 11.6%, 14.5%, 17.7%, and 10.1% respectively. In multivariable Cox proportional hazard regression analysis, we determined that age, renal dysfunction, and right ventricular systolic pressure were independently associated with the development of HF. CONCLUSIONS: This population-based study demonstrated that in PDD (stage B) HF, there was a moderate degree of progression to symptomatic (stage C) HF over 3 years, and renal dysfunction was associated with this progression independent of age, sex, hypertension, coronary disease, and ejection fraction.
BACKGROUND: Preclinical diastolic dysfunction (PDD) has been broadly defined as subjects with left ventricular diastolic dysfunction, without the diagnosis of congestive heart failure (HF) and with normal systolic function. Our objective was to determine the risk factors associated with the progression from PDD (stage B) HF to symptomatic (stage C) HF. METHODS AND RESULTS: Using the resources of the Rochester Epidemiology Project, all residents of Olmsted County, MN, who underwent echocardiography between January 1, 2004, and December 31, 2005, and had grade 2-4 diastolic dysfunction and ejection fraction ≥50% were identified. Patients with a diagnosis of HF before or within 30 days of the echocardiogram were excluded. Patients were also excluded if they had a diagnosis of atrial fibrillation or severe mitral or aortic valve regurgitation at the time of the echocardiogram. A total of 388 patients met the inclusion criteria. The mean age of the cohort was 67±12 years, with a female (57%) predominance. Prevalence of renal insufficiency (estimated glomerular filtration rate <60 mL/min per 1.73 m(2)) was 34%. The 3-year cumulative probabilities of development of (stage C) HF, development of atrial fibrillation, cardiac hospitalization, and mortality were 11.6%, 14.5%, 17.7%, and 10.1% respectively. In multivariable Cox proportional hazard regression analysis, we determined that age, renal dysfunction, and right ventricular systolic pressure were independently associated with the development of HF. CONCLUSIONS: This population-based study demonstrated that in PDD (stage B) HF, there was a moderate degree of progression to symptomatic (stage C) HF over 3 years, and renal dysfunction was associated with this progression independent of age, sex, hypertension, coronary disease, and ejection fraction.
Authors: A Al-Ahmad; W M Rand; G Manjunath; M A Konstam; D N Salem; A S Levey; M J Sarnak Journal: J Am Coll Cardiol Date: 2001-10 Impact factor: 24.094
Authors: Thomas J Wang; Jane C Evans; Emelia J Benjamin; Daniel Levy; Elizabeth C LeRoy; Ramachandran S Vasan Journal: Circulation Date: 2003-08-11 Impact factor: 29.690
Authors: Margaret M Redfield; Steven J Jacobsen; John C Burnett; Douglas W Mahoney; Kent R Bailey; Richard J Rodeheffer Journal: JAMA Date: 2003-01-08 Impact factor: 56.272
Authors: Teresa S M Tsang; Marion E Barnes; Bernard J Gersh; Yasuhiko Takemoto; A Gabriela Rosales; Kent R Bailey; James B Seward Journal: J Am Coll Cardiol Date: 2003-10-01 Impact factor: 24.094
Authors: J Woo; X Yang; L Tin Lui; Q Li; K Fai Cheng; Y Fan; F Yau; A P W Lee; J S W Lee; E Fung Journal: J Nutr Health Aging Date: 2019 Impact factor: 4.075
Authors: Zhuo Zhao; Hao Wang; Jewell A Jessup; Sarah H Lindsey; Mark C Chappell; Leanne Groban Journal: Am J Physiol Heart Circ Physiol Date: 2014-01-10 Impact factor: 4.733
Authors: Matthew Nayor; Danielle M Enserro; Vanessa Xanthakis; Martin G Larson; Emelia J Benjamin; Jayashri Aragam; Gary F Mitchell; Ramachandran S Vasan Journal: JACC Heart Fail Date: 2018-03-07 Impact factor: 12.035
Authors: Siu-Hin Wan; Paul M McKie; John A Schirger; Joshua P Slusser; David O Hodge; Margaret M Redfield; John C Burnett; Horng H Chen Journal: JACC Heart Fail Date: 2016-02-10 Impact factor: 12.035
Authors: S Michael Gharacholou; Christopher G Scott; Paul Y Takahashi; Vuyisile T Nkomo; Robert B McCully; Nowell M Fine; Patricia A Pellikka Journal: Am J Cardiol Date: 2013-04-20 Impact factor: 2.778
Authors: Heather M Prendergast; Samuel Dudley; John Kane; Martha Daviglus; Jared Marcucci; Anthony Acosta; E Bradshaw Bunney; Dejuran Richardson; Tamara O'Neal Journal: High Blood Press Cardiovasc Prev Date: 2014-09